The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
mTOR signaling at a glance
Open accessAbstract
The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival. Discoveries that have been made over the last decade show that the mTOR pathway is activated during various cellular processes (e.g. tumor formation and angiogenesis, insulin resistance, adipogenesis and T-lymphocyte activation) and is deregulated in human diseases such as cancer and type 2 diabetes. These observations have attracted broad scientific and clinical interest in mTOR. This is highlighted by the growing use of mTOR inhibitors [rapamycin and its analogues (rapalogues)] in pathological settings, including the treatment of solid tumors, organ transplantation, coronary restenosis and rheumatoid arthritis. Here, we highlight and summarize the current understanding of how mTOR nucleates distinct multi-protein complexes, how intra- and extracellular signals are processed by the mTOR complexes, and how such signals affect cell metabolism, growth, proliferation and survival.The mTOR protein is a 289-kDa serine-threonine kinase that belongs to the phospho-inositide 3-kinase (PI3K)-related kinase family and is conserved throughout evolution. The poster depicts an overview of mTOR structural domains. mTOR nucleates at least two distinct multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (reviewed by Guertin and Sabatini, 2007).mTORC1 has five components: mTOR, which is the catalytic subunit of the complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal with Sec13 protein 8 (mLST8, also known as GβL); proline-rich AKT substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-interacting protein (Deptor) (Peterson et al., 2009). The exact function of most of the mTOR-interacting proteins in mTORC1 still remains elusive. It has been proposed that Raptor might affect mTORC1 activity by regulating assembly of the complex and by recruiting substrates for mTOR (Hara et al., 2002; Kim et al., 2002). The role of mLST8 in mTORC1 function is also unclear, as deletion of this protein does not affect mTORC1 activity in vivo (Guertin et al., 2006). PRAS40 and Deptor have been characterized as distinct negative regulators of mTORC1 (Peterson et al., 2009; Sancak et al., 2007; Vander Haar et al., 2007). When the activity of mTORC1 is reduced, PRAS40 and Deptor are recruited to the complex, where they promote the inhibition of mTORC1. It was proposed that PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding (Wang et al., 2007). Upon activation, mTORC1 directly phosphorylates PRAS40 and Deptor, which reduces their physical interaction with mTORC1 and further activates mTORC1 signaling (Peterson et al., 2009; Wang et al., 2007).mTORC2 comprises six different proteins, several of which are common to mTORC1 and mTORC2: mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-activated protein kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-1); mLST8; and Deptor. There is some evidence that Rictor and mSIN1 stabilize each other, establishing the structural foundation of mTORC2 (Frias et al., 2006; Jacinto et al., 2006). Rictor also interacts with Protor-1, but the physiological function of this interaction is not clear (Thedieck et al., 2007; Woo et al., 2007). Similar to its role in mTORC1, Deptor negatively regulates mTORC2 activity (Peterson et al., 2009); so far, Deptor is the only characterized endogenous inhibitor of mTORC2. Finally, mLST8 is essential for mTORC2 function, as knockout of this protein severely reduces the stability and the activity of this complex (Guertin et al., 2006).Now that many mTOR-interacting proteins have been identified, additional biochemical studies will be needed to clarify the functions of these proteins in mTOR signaling and their potential implications in health and disease. Below, we discuss current understanding of the functions of mTORC1 and mTORC2.mTORC1 positively regulates cell growth and proliferation by promoting many anabolic processes, including biosynthesis of proteins, lipids and organelles, and by limiting catabolic processes such as autophagy. Much of the knowledge about mTORC1 function comes from the use of the bacterial macrolide rapamycin. Upon entering the cell, rapamycin binds to FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12-rapamycin binding domain (FRB) of mTOR, thus inhibiting mTORC1 functions (reviewed by Guertin and Sabatini, 2007). In contrast to its effect on mTORC1, FKBP12-rapamycin cannot physically interact with or acutely inhibit mTORC2 (Jacinto et al., 2004; Sarbassov et al., 2004). On the basis of these observations, mTORC1 and mTORC2 have been respectively characterized as the rapamycin-sensitive and rapamycin-insensitive complexes. However, this paradigm might not be entirely accurate, as chronic rapamy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Self-citationAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Self-citationDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 11×
“In response to energy depletion (low ATP:ADP ratio), AMPK is activated and phosphorylates TSC2, which increases the GAP activity of TSC2 towards Rheb and reduces mTORC1 activation (Inoki et al., 2003).”
BackgroundSelf-citationSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Self-citationMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Cited by
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464
“the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids”
BackgroundMethodInfluentialSelf-citationThe role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Delgoffe, G. M., Pollizzi, K. N., Waickman, A. T., Heikamp, E., Meyers, D. J., Horton, M. R., Xiao, B., Worley, P. F., & Powell, J. D. (2011) · Nature Immunology · doi:10.1038/ni.2005 · Cited by 1,111
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Self-citationComplement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051
Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions
Palmer, C. S., Ostrowski, M., Balderson, B., Christian, N., & Crowe, S. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00001 · Cited by 988
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B. J., Viollet, B., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.001 · Cited by 911
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
Intraovarian Control of Early Folliculogenesis
Hsueh, A. J. W., Kawamura, K., Cheng, Y., & Fauser, B. C. J. M. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1020 · Cited by 702
Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease
Donato, A. J., Machin, D. R., & Lesniewski, L. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312563 · Cited by 688
Regulation of mTORC1 and its impact on gene expression at a glance
Laplante, M., & Sabatini, D. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.125773 · Cited by 667
Self-citationThe Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo
Blagih, J., Coulombe, F., Vincent, E. E., Dupuy, F., Galicia-Vázquez, G., Yurchenko, E., Raissi, T. C., van der Windt, G. J. W., Viollet, B., Pearce, E. L., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.030 · Cited by 664
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Prabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
Metabolic switching and fuel choice during T‐cell differentiation and memory development
van der Windt, G. J. W., & Pearce, E. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01150.x · Cited by 563
“mTOR is present in two distinct complexes: mTOR complex 1 (mTORC1) and mTORC2 (88).”
BackgroundHepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 555
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
Robitaille, A. M., Christen, S., Shimobayashi, M., Cornu, M., Fava, L. L., Moes, S., Prescianotto-Baschong, C., Sauer, U., Jenoe, P., & Hall, M. N. (2013) · Science · doi:10.1126/science.1228771 · Cited by 525
Betz, C., Stracka, D., Prescianotto-Baschong, C., Frieden, M., Demaurex, N., & Hall, M. N. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302455110 · Cited by 538
“The target of rapamycin (TOR) pathway is a cellular signaling cascade that, like mitochondria, is present in all eukaryotes (28, 29).”
Cellular and molecular biology of aging endothelial cells
Donato, A. J., Morgan, R. G., Walker, A. E., & Lesniewski, L. A. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.01.021 · Cited by 538
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationA Method for the Acute and Rapid Degradation of Endogenous Proteins
Clift, D., McEwan, W. A., Labzin, L. I., Konieczny, V., Mogessie, B., James, L. C., & Schuh, M. (2017) · Cell · doi:10.1016/j.cell.2017.10.033 · Cited by 531
Heterotopic Ossification: A Comprehensive Review
Meyers, C., Lisiecki, J., Miller, S., Levin, A., Fayad, L., Ding, C., Sono, T., McCarthy, E., Levi, B., & James, A. W. (2019) · JBMR Plus · doi:10.1002/jbm4.10172 · Cited by 506
Obesity, inflammation, and liver cancer
Sun, B., & Karin, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.020 · Cited by 496
Anti-cancer chalcones: Structural and molecular target perspectives
Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 495
Axon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 486
p62 Is a Key Regulator of Nutrient Sensing in the mTORC1 Pathway
Duran, A., Amanchy, R., Linares, J. F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., & Diaz-Meco, M. T. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.038 · Cited by 472
Lee, K., Gudapati, P., Dragovic, S., Spencer, C., Joyce, S., Killeen, N., Magnuson, M. A., & Boothby, M. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.002 · Cited by 464
Insulin signaling in health and disease
Saltiel, A. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142241 · Cited by 446
Insulin signaling meets mitochondria in metabolism
Cheng, Z., Tseng, Y., & White, M. F. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.005 · Cited by 449
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Metabolic pathways in T cell fate and function
Gerriets, V. A., & Rathmell, J. C. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.010 · Cited by 436
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420
“Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis.”
BackgroundInfluentialDin, F. V. N., Valanciute, A., Houde, V. P., Zibrova, D., Green, K. A., Sakamoto, K., Alessi, D. R., & Dunlop, M. G. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.050 · Cited by 418
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Atherton, P. J., Etheridge, T., Watt, P. W., Wilkinson, D., Selby, A., Rankin, D., Smith, K., & Rennie, M. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29819 · Cited by 404
PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
Fattahi, S., Amjadi-Moheb, F., Tabaripour, R., Ashrafi, G. H., & Akhavan-Niaki, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118513 · Cited by 400
Primary cilia regulate mTORC1 activity and cell size through Lkb1
Boehlke, C., Kotsis, F., Patel, V., Braeg, S., Voelker, H., Bredt, S., Beyer, T., Janusch, H., Hamann, C., Gödel, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2117 · Cited by 388
Beclin-1-Dependent Autophagy Protects the Heart During Sepsis
Sun, Y., Yao, X., Zhang, Q.-J., Zhu, M., Liu, Z.-P., Ci, B., Xie, Y., Carlson, D., Rothermel, B. A., Sun, Y., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032821 · Cited by 374
An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness
Procaccini, C., De Rosa, V., Galgani, M., Abanni, L., Calì, G., Porcellini, A., Carbone, F., Fontana, S., Horvath, T. L., La Cava, A., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.024 · Cited by 368
Melzer, D., Pilling, L. C., & Ferrucci, L. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0183-6 · Cited by 363
Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?
Görlach, A., Dimova, E. Y., Petry, A., Martínez-Ruiz, A., Hernansanz-Agustín, P., Rolo, A. P., Palmeira, C. M., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.016 · Cited by 351
Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders
Doyle, K. M., Kennedy, D., Gorman, A. M., Gupta, S., Healy, S. J. M., & Samali, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01374.x · Cited by 321
Commentary: IL-4 and IL-13 receptors and signaling
McCormick, S. M., & Heller, N. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.023 · Cited by 317
Collins, B. C., Gillet, L. C., Rosenberger, G., Röst, H. L., Vichalkovski, A., Gstaiger, M., & Aebersold, R. (2013) · Nature Methods · doi:10.1038/nmeth.2703 · Cited by 314
The Roles of mTOR Complexes in Lipid Metabolism
Caron, A., Richard, D., & Laplante, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034355 · Cited by 314
Self-citationConnecting Mitochondria, Metabolism, and Stem Cell Fate
Wanet, A., Arnould, T., Najimi, M., & Renard, P. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0117 · Cited by 313
Interplay between FOXO, TOR, and Akt
Hay, N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.013 · Cited by 311
Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 311
Compartment-Specific Regulation of Autophagy in Primary Neurons
Maday, S., & Holzbaur, E. L. F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4401-15.2016 · Cited by 309
“Active mTORC1 phosphorylates S6 kinase, which in turn phosphorylates ribosomal S6 (Laplante and Sabatini, 2009).”
BackgroundROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy
Dewaele, M., Maes, H., & Agostinis, P. (2010) · Autophagy · doi:10.4161/auto.6.7.12113 · Cited by 306
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications
Ostrovidov, S., Hosseini, V., Ahadian, S., Fujie, T., Parthiban, S. P., Ramalingam, M., Bae, H., Kaji, H., & Khademhosseini, A. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0534 · Cited by 302
“This important regulation is mainly controlled by the mammalian target of rapamycin (mTOR) signaling pathway.(166) mTOR is a 289-kDa serine/threonine kinase that forms two different complexes 1 (mTORC1) and 2 (mTORC2), respectively, sensitive and insensitive to rapamycin.”
Procaccini, C., Jirillo, E., & Matarese, G. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.012 · Cited by 299
Posttranslational modification of autophagy-related proteins in macroautophagy
Xie, Y., Kang, R., Sun, X., Zhong, M., Huang, J., Klionsky, D. J., & Tang, D. (2015) · Autophagy · doi:10.4161/15548627.2014.984267 · Cited by 302
The multiple roles of autophagy in cancer
Rosenfeldt, M. T., & Ryan, K. M. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr031 · Cited by 300
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
Sparks, C. A., & Guertin, D. A. (2010) · Oncogene · doi:10.1038/onc.2010.139 · Cited by 299
mTOR Pathways in Cancer and Autophagy
Paquette, M., El-Houjeiri, L., & Pause, A. (2018) · Cancers · doi:10.3390/cancers10010018 · Cited by 297
Paradigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293
Leucine and mTORC1: a complex relationship
Dodd, K. M., & Tee, A. R. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00525.2011 · Cited by 293
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
The Emerging Roles of mTORC1 in Macromanaging Autophagy
Dossou, A. S., & Basu, A. (2019) · Cancers · doi:10.3390/cancers11101422 · Cited by 288
Dickinson, J. M., Fry, C. S., Drummond, M. J., Gundermann, D. M., Walker, D. K., Glynn, E. L., Timmerman, K. L., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.139485 · Cited by 282
Connecting mTORC1 signaling to SREBP-1 activation
Bakan, I., & Laplante, M. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dd03 · Cited by 281
Self-citationResveratrol induces autophagy by directly inhibiting mTOR through ATP competition
Park, D., Jeong, H., Lee, M. N., Koh, A., Kwon, O., Yang, Y. R., Noh, J., Suh, P.-G., Park, H., & Ryu, S. H. (2016) · Scientific Reports · doi:10.1038/srep21772 · Cited by 281
Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Mirzaa, G. M., Campbell, C. D., Solovieff, N., Goold, C. P., Jansen, L. A., Menon, S., Timms, A. E., Conti, V., Biag, J. D., Olds, C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0363 · Cited by 273
mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1–JNK pathway
Kato, H., Nakajima, S., Saito, Y., Takahashi, S., Katoh, R., & Kitamura, M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.98 · Cited by 272
Fonseca, B. D., Zakaria, C., Jia, J.-J., Graber, T. E., Svitkin, Y., Tahmasebi, S., Healy, D., Hoang, H.-D., Jensen, J. M., Diao, I. T., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.621730 · Cited by 266
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Pantovic, A., Krstic, A., Janjetovic, K., Kocic, J., Harhaji-Trajkovic, L., Bugarski, D., & Trajkovic, V. (2013) · Bone · doi:10.1016/j.bone.2012.10.024 · Cited by 262
Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential
Yang, D., Livingston, M. J., Liu, Z., Dong, G., Zhang, M., Chen, J.-K., & Dong, Z. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2639-1 · Cited by 252
DNA Damage Triggers Golgi Dispersal via DNA-PK and GOLPH3
Farber-Katz, S. E., Dippold, H. C., Buschman, M. D., Peterman, M. C., Xing, M., Noakes, C. J., Tat, J., Ng, M. M., Rahajeng, J., Cowan, D. M., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.023 · Cited by 257
Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
Kaizuka, T., Hara, T., Oshiro, N., Kikkawa, U., Yonezawa, K., Takehana, K., Iemura, S.-I., Natsume, T., & Mizushima, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121699 · Cited by 255
The liver kinase B1 is a central regulator of T cell development, activation, and metabolism
MacIver, N. J., Blagih, J., Saucillo, D. C., Tonelli, L., Griss, T., Rathmell, J. C., & Jones, R. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100367 · Cited by 235
Insulin Signal Transduction Perturbations in Insulin Resistance
Khalid, M., Alkaabi, J., Khan, M. A. B., & Adem, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168590 · Cited by 233
Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model
Ricciardi, S., Boggio, E. M., Grosso, S., Lonetti, G., Forlani, G., Stefanelli, G., Calcagno, E., Morello, N., Landsberger, N., Biffo, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq563 · Cited by 223
Stressin’ Sestrins take an aging fight
Budanov, A. V., Lee, J. H., & Karin, M. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000097 · Cited by 208
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
Xie, L., Sun, F., Wang, J., Mao, X., Xie, L., Yang, S.-H., Su, D.-M., Simpkins, J. W., Greenberg, D. A., & Jin, K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303492 · Cited by 175
“under physiological and pathological conditions (7, 8).”
Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
Salussolia, C. L., Klonowska, K., Kwiatkowski, D. J., & Sahin, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015354 · Cited by 163
A model of the mitochondrial basis of bipolar disorder
Morris, G., Walder, K., McGee, S. L., Dean, O. M., Tye, S. J., Maes, M., & Berk, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.014 · Cited by 162
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Connecting metabolism and reproduction: roles of central energy sensors and key molecular mediators
Roa, J., & Tena-Sempere, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.027 · Cited by 136
“The mTOR system exists as two distinct multimolecular complexes: mTOR complex 1 (mTORC1) and mTORC2 (Laplante and Sabatini, 2009).”
Skeletal muscle gene expression in response to resistance exercise: sex specific regulation
Liu, D., Sartor, M. A., Nader, G. A., Gutmann, L., Treutelaar, M. K., Pistilli, E. E., IglayReger, H. B., Burant, C. F., Hoffman, E. P., & Gordon, P. M. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-659 · Cited by 122
“Several negative regulators have been identified including DNA-damage-inducible transcript 4 (DDIT4, also known as REDD1), DNAdamage-inducible transcript 4-like (DDIT4L, also known as REDD2), AKT1 substrate 1 (proline-rich) (AKT1S1, also known as PRAS40), and tuberous sclerosis 1 and 2 (TSC1/TSC2) [47].”
BackgroundYasuda, M., Tanaka, Y., Kume, S., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Koya, D., Haneda, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.001 · Cited by 123
“mTORC1 is finally activated by a small GTPase, the Ras homolog enriched in brain (Rheb), that is anchored to lysosomal membranes [21].”
Reelin in the years: controlling neuronal migration and maturation in the mammalian brain
D'Arcangelo, G. (2014) · Advances in Neuroscience · doi:10.1155/2014/597395 · Cited by 120
Wei, Y.-N., Hu, H.-Y., Xie, G.-C., Fu, N., Ning, Z.-B., Zeng, R., & Khaitovich, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0608-2 · Cited by 117
Dysfunction of Optineurin in Amyotrophic Lateral Sclerosis and Glaucoma
Toth, R. P., & Atkin, J. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01017 · Cited by 114
Head, S. A., Shi, W., Zhao, L., Gorshkov, K., Pasunooti, K., Chen, Y., Deng, Z., Li, R.-J., Shim, J. S., Tan, W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512867112 · Cited by 111
Kim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107
Energy balance and puberty onset: Emerging role of central mTOR signaling
Roa, J., & Tena-Sempere, M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.05.003 · Cited by 106
Metadata
- Authors
- Laplante, M., & Sabatini, D. M.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2009-10-15
- Volume
- 122
- Issue
- 20
- Pages
- 3589-3594
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2143112776
- Cited by
- 2,170
- References
- 72
- FWCI
- 35.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.